Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

SELECT A CONDITION
PATIENT SUPPORT PROGRAM
Skip to main content
Hamburger button
Close button
SELECT A CONDITION

UNDERSTANDING PH-ILD

View sub items for UNDERSTANDING PH-ILD

ABOUT TYVASO

View sub items for ABOUT TYVASO

WHY TAKE TYVASO?

View sub items for WHY TAKE TYVASO?

TAKING TYVASO

View sub items for TAKING TYVASO

SUPPORT & RESOURCES

View sub items for SUPPORT & RESOURCES
Colorful bubbles

HOW PH-ILD PROGRESSES

It’s important to be checked for PH regularly because PH can appear at any time as your ILD progresses.

PH-ILD stages of progression
PH-ILD stages of progression

ILD causes lung tissue to become stiff, making it harder to breathe and get oxygen into the blood.

PH-ILD stages of progression

PH causes the blood vessels in the lungs to become narrow, making it harder for blood to flow and causing pressure to increase.

PH-ILD stages of progression

The heart has to work harder to push blood through the lungs, which weakens or damages the heart.

Treatment with TYVASO can reduce the risk of PH-ILD getting worse.

Find out how

How common is PH in patients with ILD?

PH is sometimes present even when someone is first diagnosed with interstitial lung disease, such as IPF.

Learn about PH-ILD Diagnosis

IMPORTANT SAFETY
INFORMATION

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
EXPAND

IMPORTANT SAFETY
INFORMATION

COLLAPSE

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
  • Have asthma or chronic obstructive pulmonary disease (COPD)
  • Are pregnant or plan to become pregnant. It is not known if either product will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if either product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Either product and other medicines may affect each other.

Especially tell your healthcare provider if you take:

  • Medicines used to treat high blood pressure or heart disease
  • Medicines that decrease blood clotting (anticoagulants)
  • Water pills (diuretics)
  • Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of TYVASO or TYVASO DPI?

Both products can cause serious side effects, including:

  • Low blood pressure (symptomatic hypotension). If you have low blood pressure, either product may lower your blood pressure more.
  • Bleeding problems. Either product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of both products are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking TYVASO or TYVASO DPI because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at

You are now leaving the Tyvaso.com website

This link will take you to a site maintained by a third party who is solely responsible for the site’s content. Click CONTINUE to proceed or CLOSE to return to www.TYVASO.com.

CONTINUE
www.fda.gov/MedWatch
or call 1-800-FDA-1088.

What are TYVASO and TYVASO DPI?

TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prescription medicines used in adults to treat:

  • Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO or TYVASO DPI can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking TYVASO or TYVASO DPI. It is not known if TYVASO or TYVASO DPI is safe and effective in children under 18 years of age.
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. TYVASO or TYVASO DPI can improve the ability to exercise.

The risk information provided here is not comprehensive. To learn more about TYVASO or TYVASO DPI, talk with your healthcare provider. Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI™ Inhalation Powder, and additional information at www.TYVASO.com or call 1-877-UNITHER (1-877-864-8437).


TYVISIconMAY2022

Drug Discard ProgramPrivacy PolicyTerms of UseContact UsSite Map

TYVASO and TYVASO DPI are registered trademarks of United Therapeutics Corporation.

All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.

© 2022 United Therapeutics Corporation. All rights reserved. US/TYV/0571

NOW APPROVED—TYVASO DPI® FITS IN THE PALM OF YOUR HAND

Ask your healthcare provider about the
Dry Powder Inhaler (DPI) option now approved for TYVASO®.

bubbles pattern
hand holding dpi devicebubbles pattern

See how simple TYVASO DPI is to use.

LEARN MORE
bubbles pattern

YOU ARE NOW LEAVING THE TYVASO.COM WEBSITE

This link will take you to a site maintained by a third party who is solely responsible for the site’s content. Click CONTINUE to proceed or CLOSE to return to tyvaso.com

Close
Continue